Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $619.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price upped by Cantor Fitzgerald from $595.00 to $619.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the pharmaceutical company’s stock.

Several other research firms also recently issued reports on VRTX. Morgan Stanley initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 1st. They set an “overweight” rating and a $665.00 target price on the stock. Stifel Nicolaus set a $500.00 price target on Vertex Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, August 4th. Rothschild & Co Redburn boosted their price objective on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Truist Financial increased their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group raised their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $596.44.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $542.50 on Tuesday. The firm has a market cap of $137.69 billion, a P/E ratio of 34.91, a price-to-earnings-growth ratio of 2.84 and a beta of 0.28. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The company’s 50 day moving average is $522.81 and its 200-day moving average is $481.42. Vertex Pharmaceuticals has a 12-month low of $406.67 and a 12-month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the business posted $4.80 earnings per share. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. Sell-side analysts predict that Vertex Pharmaceuticals will post 16.50 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VRTX. Summit Global Investments purchased a new position in Vertex Pharmaceuticals during the 2nd quarter valued at $3,568,000. Calamos Advisors LLC raised its holdings in Vertex Pharmaceuticals by 77.1% in the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after purchasing an additional 33,917 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth $13,823,000. UNIVEST FINANCIAL Corp purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $4,495,000. Finally, Meeder Advisory Services Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $3,187,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.